Industry News
Biotechnology Industry News
RevHealth CEO Ben Beckley shares…
RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.
The first-in-class EGFRxHER3…
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2 agents in triple-negative breast cancer.
Rallybio has steered its way to a…
Rallybio has steered its way to a new reverse merger, inking a deal with Avenzo Therapeutics weeks after a UCB buyout took its former partner off the market.
Days after its lead clinical-stage…
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
Within hours of securing a…
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China’s Haisco Pharmaceutical.
Servier has struck a deal to buy…
Servier has struck a deal to buy Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, gaining control of a program that is on course to deliver pivotal data this year.
Eli Lilly has expanded its…
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
David Cade, the chief medical…
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s
Kelonia Therapeutics has shared…
Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech.
In the race to forge the next…
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung
This year’s meeting of the…
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year. But even as competitors swirl,
The German biotech shared updated…
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year.
Nine years after wowing the…
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D.,
SK pharmteco CEO Joerg Ahlgrimm…
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.
AstraZeneca has shared data it…
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified subgroup.
Agios Pharmaceuticals’ next-gen…
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).
Senior Writer Darren Incorvaia…
Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship Pioneering, MassBio and PassKey about funding pressures, AI, China's biotech ecosystem and what's next for drug development.
Pfizer is paying Innovent $650…
Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s fast early development system.
Gilead has abandoned work on the…
Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field.
After more than eight years at the…
After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zachary Roberts, M.D., Ph.D., the biotech’s chief medical officer and head